ELI LILLY & Co — Director's Dealing 2022

Feb 12, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ELI LILLY & Co (LLY)
CIK: 0000059478
Period of Report: 2022-02-09

Reporting Person: Mason Michael B (Sr. VP & Pres., Lilly Diabetes)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-02-09	Common Stock	A	2612	$243.27	Acquired	27506	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-09	Restricted Stock Unit	$	A	6690	Acquired	2023-02-01	Common Stock (6690.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	935	Indirect

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.